Equities

Katakura Industries Co Ltd

Katakura Industries Co Ltd

Actions
IndustrialsGeneral Industrials
  • Price (JPY)1,908.00
  • Today's Change20.00 / 1.06%
  • Shares traded31.70k
  • 1 Year change+6.00%
  • Beta0.6890
Data delayed at least 20 minutes, as of May 21 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Katakura Industries Co.,Ltd. is a Japan-based company mainly engaged in the real estate operation and leasing, as well as the manufacture and sale of mechanical maintenance products and auto parts. The Company operates through four business segments. The Textile segment is engaged in the manufacture and sale of underwear, socks, silk products, casual innerwear, adjusted underwear and functional fibers, as well as the brand licensing business. The Pharmaceutical segment manufactures and sells ethical drugs. The Machinery-Related segment manufactures and sells fire trucks, automobile parts, agricultural machinery and imports and sells petroleum products. The Real Estate segment operates shopping centers and rents real estate. The Company is also involved in the home improvement, building management services, sales of flower visiting insects, low potassium lettuce, production and sales of Hanabiratake and day services.

  • Revenue in JPY (TTM)39.83bn
  • Net income in JPY3.01bn
  • Incorporated1920
  • Employees1.04k
  • Location
    Katakura Industries Co LtdNichirei Akashicho Bldg.6-4, Akashi-choCHUO-KU 104-8312JapanJPN
  • Phone+81 368321873
  • Fax+81 368320256
  • Websitehttps://www.katakura.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Koa Shoji Holdings Co Ltd22.67bn2.87bn34.98bn297.0012.191.549.771.5472.4572.45572.11573.530.78785.562.6276,317,420.009.987.9112.089.9329.9528.7412.6610.483.8636.550.114219.648.358.2713.9029.60-21.2615.52
Daito Pharmaceutical Co Ltd45.19bn3.28bn36.18bn1.01k11.090.6965.330.8007207.85207.852,864.813,311.810.61931.812.6544,701,280.004.356.995.649.2921.3822.717.038.831.15--0.123117.083.772.49-22.883.437.4812.70
Fuji Pharma Co Ltd43.05bn5.92bn37.58bn1.62k6.230.83764.080.8728243.57243.571,771.381,812.380.50711.343.2126,558,910.006.974.1010.565.5839.7842.4113.757.550.5895--0.382631.1715.421.5227.410.370919.045.73
Seikagaku Corp36.21bn2.19bn44.54bn976.0019.560.591811.441.2340.0840.08663.801,324.810.46012.065.02--2.780.42613.050.467846.6054.186.040.98144.47--0.0055415.528.244.99-2.24-0.522430.280.00
Shin Nippon Biomedical Laboratories Ltd26.45bn5.53bn56.62bn1.21k10.241.6611.032.14132.86132.86635.35819.430.39611.245.08--8.2610.5412.4315.9354.0052.7320.8625.320.7835--0.433924.215.4211.05-8.7323.1850.9075.54
Katakura Industries Co., Ltd.39.83bn3.01bn66.49bn1.04k20.770.811211.291.6790.9090.901,203.272,327.460.28582.354.4938,300,000.002.292.352.993.3438.3037.758.018.322.58--0.109718.8116.62-2.048.0918.87-7.4610.76
ispace Inc2.36bn-2.37bn69.01bn216.00--7.08--29.28-31.36-31.3629.06104.640.13777.4898.55---13.83---24.15--39.38---100.39--2.05--0.5623--138.27--79.24------
ASKA Pharmaceutical Holdings Co Ltd62.84bn7.55bn69.81bn747.008.571.048.171.11266.48266.482,219.592,186.080.70661.694.08--8.484.6311.085.8748.8046.9412.016.761.49--0.132814.423.946.1278.0334.04-37.8923.36
JCR Pharmaceuticals Co Ltd42.87bn5.51bn82.48bn879.0014.481.4111.081.9243.9143.91342.28450.130.43490.58913.29--5.628.668.4713.4672.9074.5112.9218.241.2227.690.292129.6024.8313.1146.008.1918.5421.67
Eiken Chemical Co Ltd40.05bn2.63bn82.71bn754.0030.431.6219.362.0770.5270.521,080.891,328.720.62622.833.40--4.128.015.0610.1441.7645.926.5811.502.62--0.086235.21-7.442.29-54.08-5.2411.6611.20
Data as of May 21 2024. Currency figures normalised to Katakura Industries Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

9.93%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 09 May 2024663.48k1.88%
Nomura Asset Management Co., Ltd.as of 30 Apr 2024562.90k1.60%
Morant Wright Management Ltd.as of 31 Mar 2024442.00k1.26%
Dimensional Fund Advisors LPas of 30 Apr 2024433.38k1.23%
Andbank Asset Management Luxembourg SAas of 30 Jun 2023407.00k1.16%
Nikko Asset Management Co., Ltd.as of 10 May 2024272.70k0.77%
Daiwa Asset Management Co. Ltd.as of 29 Mar 2024257.40k0.73%
Norges Bank Investment Managementas of 31 Dec 2023187.20k0.53%
Gutmann KAGas of 31 Jan 2024155.50k0.44%
Mitsubishi UFJ Asset Management Co., Ltd.as of 10 May 2024113.70k0.32%
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.